Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Alain Dupuy
Based on 3 articles published since 2008
||||

Between 2008 and 2019, Alain Dupuy wrote the following 3 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline [Guidelines for stage I to III melanoma]. 2016

Guillot, Bernard / Dalac, Sophie / Denis, Marc / Dupuy, Alain / Emile, Jean François / De La Fouchardiere, Arnaud / Hindie, Elif / Jouary, Thomas / Lassau, Nathalie / Mirabel, Xavier / Piperno Neumann, Sophie / De Raucourt, Sixtine / Vanwijck, Romain. ·Département de dermatologie, hôpital Saint-Eloi, CHU de Montpellier, 34295 Montpellier cedex 5, France. Electronic address: b-guillot@chu-montpellier.fr. · Service de dermatologie, hôpital du Bocage sud, CHU de Dijon, BP 1542, 21079 Dijon cedex, France. · Laboratoire de biochimie, institut de biologie, 9, quai Moncousu, 44093 Nantes cedex, France. · Service de dermatologie, CHU de Rennes, Rennes, France. · Service d'anatomie pathologique, CHU Ambroise-Paré Boulogne, 92104 Boulogne cedex, France. · Centre anticancéreux Léon-Bérard, 28, rue Laennec, 69008 Lyon, France. · Service de médecine nucléire sud et pellegrin, CHU de Bordeaux, Bordeaux, France. · Service de médecine, CH de Pau, 64000 Pau, France. · Service d'imagerie médicale, institut Gustave-Roussy, 94800 Villejuif, France. · Centre Oscar-Lambret, 3, rue Fréderic-Combemale, 59000 Lille, France. · Institut Curie, 26, rue d'Ulm, 75005 Paris, France. · Sixtine, 1, avenue du 6 juin, 14000 Caen, France. · Université catholique de Louvain, avenue Hippocrate, 10 B-1200 Bruxelles, Belgique. ·Bull Cancer · Pubmed #27456259.

ABSTRACT: -- No abstract --

2 Review Do the Side Effects of BRAF Inhibitors Mimic RASopathies? 2017

Sfecci, Alicia / Dupuy, Alain / Dinulescu, Monica / Droitcourt, Catherine / Adamski, Henri / Hadj-Rabia, Smail / Odent, Sylvie / Galibert, Marie-Dominique / Boussemart, Lise. ·Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France. · Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France; Division of Medicine, Université de Rennes 1, Rennes, France; CNRS UMR6290, GEO team, IGDR, Rennes, France. · Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France; Division of Medicine, Université de Rennes 1, Rennes, France. · Department of Dermatology, Centre National de Référence des Maladies Génétiques à Expression Cutanée (MAGEC), Hôpital Universitaire Necker-Enfants Malades, APHP, Institut Imagine, Paris, France; Unité INSERM U1163, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Paris, France. · Division of Medicine, Université de Rennes 1, Rennes, France; Department of Clinical Genetics, Centre de Référence des Anomalies du Développement CLAD-Ouest, CNRS UMR 6290, Sud Hospital, CHU de Rennes, Rennes, France. · Division of Medicine, Université de Rennes 1, Rennes, France; CNRS UMR6290, GEO team, IGDR, Rennes, France; Department of Somatic Cancer Genetics, Pontchaillou Hospital, CHU de Rennes, Rennes, France. · Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France; Division of Medicine, Université de Rennes 1, Rennes, France; CNRS UMR6290, GEO team, IGDR, Rennes, France. Electronic address: lise.boussemart@chu-rennes.fr. ·J Invest Dermatol · Pubmed #28340684.

ABSTRACT: Recent advances in targeted anticancer therapies have substantially improved the prognosis of several cancers. Such targeted therapies are not, however, free of side effects, and these side effects are clearly distinct from those induced by classical cytotoxic chemotherapies. This is likely so because targeted therapies are designed to interfere with specific oncogenic signaling pathways rather than to inhibit cell proliferation in general. In fact, interference with specific signaling pathways may lead to effects that mimic those associated with genetic disorders due to alterations in the corresponding signaling pathways. Here, we compare the clinical effects of treatment with BRAF inhibitors with those of genetic RASopathies and find a striking overlap between the inhibitor-induced, iatrogenic dermatoses with the genodermatoses seen in patients with corresponding congenital RASopathies. We hope that such comparisons lead to a better understanding of the side effects of targeted therapies.

3 Minor SPECT/CT for sentinel lymph node detection in patients with melanoma. 2013

Dupuy, Alain / Heusse, Jean-Laurent. · ·JAMA · Pubmed #23321749.

ABSTRACT: -- No abstract --